Canada's Angiochem outlines plans for advancing product candidates and deal with Geron

Privately-held Canadian group Angiochem has announced its plans for advancing the development of product candidates from its pipeline, using the company’s proprietary platform for Engineered Peptide Compounds (EPiC) for drugs that cross the blood-brain barrier through LRP-1 targeting.

The product candidates cover a range of therapeutic areas, including pain, obesity and Parkinson’s disease, using Angiochem’s technology to uniquely enable drugs to penetrate the CNS, including biologics (peptides and proteins) and small molecules. In addition, Angiochem will continue to actively pursue additional research and development collaborations.

"We are excited to move forward with our diverse product portfolio, based on the validation of our receptor-targeting peptide technology and the strengthened resources provided by the $35 million up-front payment, comprised of $7.5 million in cash and $27.5 million of shares of Geron (Nasdaq: GERN) common stock to be issued in January 2011, related to the recently announced license and collaboration agreements with Geron,” commented Jean-Paul Castaigne, president and chief of Angiochem.